华东医药：自研创新药HDM1005的体重管理和糖尿病适应症2期临床正分别按计划开展，且进展顺利

Group 1 - The company is progressing well with its self-developed innovative drug HDM1005, targeting weight management and diabetes indications in Phase II clinical trials [2] - Topline data for the weight management indication is expected to be available by the end of this year, with results to be announced through official announcements or at major international academic conferences [2] - Preparations for the Phase III clinical trial of HDM1005 for weight management have already begun [2]